Citadel Advisors’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$338M Sell
12,053,900
-6,876,000
-36% -$183M 0.05% 277
2025
Q4
$471M Buy
18,929,900
+4,429,400
+31% +$112M 0.07% 202
2025
Q3
$369M Sell
14,500,500
-1,476,700
-9% -$36.4M 0.06% 266
2025
Q2
$387M Sell
15,977,200
-3,559,300
-18% -$83M 0.07% 210
2025
Q1
$495M Buy
19,536,500
+1,204,000
+7% +$31.5M 0.09% 130
2024
Q4
$486M Sell
18,332,500
-6,494,100
-26% -$176M 0.08% 150
2024
Q3
$718M Sell
24,826,600
-4,764,000
-16% -$139M 0.14% 86
2024
Q2
$828M Buy
29,590,600
+1,022,900
+4% +$28.2M 0.17% 74
2024
Q1
$793M Buy
28,567,700
+7,386,400
+35% +$205M 0.15% 75
2023
Q4
$610M Buy
21,181,300
+2,295,400
+12% +$69.4M 0.12% 89
2023
Q3
$626M Buy
18,885,900
+1,480,400
+9% +$52.4M 0.13% 74
2023
Q2
$638M Buy
17,405,500
+9,277,000
+114% +$361M 0.13% 74
2023
Q1
$332M Sell
8,128,500
-5,171,300
-39% -$223M 0.07% 172
2022
Q4
$681M Buy
13,299,800
+5,719,400
+75% +$274M 0.16% 70
2022
Q3
$332M Buy
7,580,400
+203,300
+3% +$9.88M 0.08% 165
2022
Q2
$387M Sell
7,377,100
-2,537,400
-26% -$129M 0.1% 123
2022
Q1
$513M Buy
9,914,500
+2,031,300
+26% +$105M 0.11% 104
2021
Q4
$466M Sell
7,883,200
-2,684,800
-25% -$133M 0.1% 123
2021
Q3
$455M Buy
10,568,000
+2,717,100
+35% +$120M 0.09% 134
2021
Q2
$307M Sell
7,850,900
-4,451,000
-36% -$173M 0.07% 191
2021
Q1
$446M Sell
12,301,900
-365,100
-3% -$13M 0.11% 102
2020
Q4
$466M Buy
12,667,000
+5,921,611
+88% +$217M 0.12% 96
2020
Q3
$235M Buy
6,745,389
+2,478,481
+58% +$86.9M 0.07% 159
2020
Q2
$132M Buy
4,266,908
+258,124
+6% +$8.77M 0.05% 300
2020
Q1
$124M Buy
4,008,784
+141,869
+4% +$4.83M 0.06% 266
2019
Q4
$144M Sell
3,866,915
-755,297
-16% -$26.9M 0.06% 269
2019
Q3
$158M Buy
4,622,212
+2,055,933
+80% +$74.8M 0.07% 220
2019
Q2
$105M Sell
2,566,279
-281,418
-10% -$11.2M 0.05% 381
2019
Q1
$115M Buy
2,847,697
+1,024,382
+56% +$41M 0.06% 311
2018
Q4
$75.5M Buy
1,823,315
+530,373
+41% +$22M 0.04% 433
2018
Q3
$54.1M Sell
1,292,942
-184,239
-12% -$7.09M 0.02% 719
2018
Q2
$50.8M Buy
1,477,181
+351,614
+31% +$12M 0.03% 695
2018
Q1
$37.9M Sell
1,125,567
-168,640
-13% -$5.8M 0.02% 734
2017
Q4
$44.5M Buy
1,294,207
+146,085
+13% +$4.98M 0.03% 677
2017
Q3
$38.9M Sell
1,148,122
-25,402
-2% -$816K 0.03% 674
2017
Q2
$37.4M Sell
1,173,524
-536,907
-31% -$16.9M 0.03% 635
2017
Q1
$55.5M Sell
1,710,431
-782,490
-31% -$24.7M 0.05% 399
2016
Q4
$76.8M Buy
2,492,921
+941,328
+61% +$28.7M 0.08% 231
2016
Q3
$49.9M Sell
1,551,593
-830,447
-35% -$27.8M 0.05% 384
2016
Q2
$79.6M Buy
2,382,040
+407,687
+21% +$13M 0.09% 192
2016
Q1
$55.5M Buy
1,974,353
+1,092,682
+124% +$31.2M 0.07% 262
2015
Q4
$27M Sell
881,671
-227,875
-21% -$7.17M 0.03% 672
2015
Q3
$33.1M Buy
1,109,546
+294,382
+36% +$9.44M 0.03% 611
2015
Q2
$25.9M Buy
815,164
+196,150
+32% +$6.39M 0.02% 845
2015
Q1
$20.4M Sell
619,014
-240,101
-28% -$7.63M 0.02% 968
2014
Q4
$25.4M Buy
859,115
+123,107
+17% +$3.53M 0.03% 801
2014
Q3
$20.6M Sell
736,008
-75,361
-9% -$2.12M 0.02% 884
2014
Q2
$22.8M Sell
811,369
-225,662
-22% -$6.43M 0.03% 729
2014
Q1
$31.6M Sell
1,037,031
-57,232
-5% -$1.71M 0.04% 582
2013
Q4
$31.8M Buy
1,094,263
+221,340
+25% +$6.44M 0.04% 561
2013
Q3
$23.8M Buy
872,923
+70,091
+9% +$1.91M 0.04% 641
2013
Q2
$21.3M Buy
+802,832
New +$22.2M 0.04% 629

Other funds holding PFE

Citadel Advisors's PFE Position: Q1 2026 in Review

Citadel Advisors increased its Pfizer (PFE) stake by 36% in Q1 2026, buying an estimated $52M and bringing the position to 7,359,865 shares worth $207M. The position accounts for 0.03% of the portfolio, ranked #443.

Citadel Advisors first reported a position in PFE in Q2 2013 and has held it in 52 quarters since. The position peaked at $571M in Q2 2024. 2,937 funds tracked by Wall St. Rank hold PFE as of Q1 2026.

  • Citadel Advisors held 7,359,865 shares of Pfizer worth $207M as of Q1 2026.
  • Citadel Advisors bought 1,952,489 Pfizer shares in Q1 2026, an estimated $52M.
  • Pfizer made up 0.03% of Citadel Advisors's portfolio in Q1 2026, its #443 holding.
  • Citadel Advisors first reported a position in Pfizer in Q2 2013 and has held it in 52 quarters since.
  • Citadel Advisors's Pfizer position peaked at $571M in Q2 2024.
  • 2,937 funds tracked by Wall St. Rank held Pfizer as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.